Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

The California Plasma Coalition (CalPlasma) today launched a statewide campaign to raise awareness of the vital role that plasma donations play in saving lives of Californians and patients around the ...

new launches like Abrysvo and newly acquired products like Nurtec as well as those acquired from Seagen (December 2023). The trend is expected to have continued in the fourth quarter. In the past ...

Hemophilia growth was 11% ... Our Phase 3 study evaluating RiaSTAP for the treatment of acquired fibrinogen deficiency is progressing in Europe and we are preparing for a filing in the US.

Nature Research Intelligence Topics enable transformational understanding and discovery in research by categorising any document into meaningful, accessible topics. Read this blog to understand ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings ...

In hemophilia, an increasing number of patients ... preferably through block trades and in the open market. Shares acquired will be canceled and will have an accretive effect to Sanofi's earning ...

Hemophilia: Hemophilia is a genetic disorder ... Paroxysmal Nocturnal Hemoglobinuria (PNH): PNH is a rare acquired blood disorder characterized by the destruction of red blood cells, white blood ...